2020
Blutaparon portulacoides ethanolic extract reduced IL-1β and inflammatory parameters induced by the Mycobacterium complex and carrageenan in mice
Kassuya R, Radai J, Macorini L, Nunes V, Salvador M, Leite P, Oliveira R, Croda J, Arena A, Kassuya C. Blutaparon portulacoides ethanolic extract reduced IL-1β and inflammatory parameters induced by the Mycobacterium complex and carrageenan in mice. Inflammopharmacology 2020, 29: 439-450. PMID: 32910315, DOI: 10.1007/s10787-020-00752-0.Peer-Reviewed Original ResearchMeSH KeywordsAmaranthaceaeAnimalsAnti-Inflammatory AgentsAntitubercular AgentsCarrageenanDisease Models, AnimalDose-Response Relationship, DrugEdemaFemaleInflammationInterleukin-1betaMaleMiceMice, Inbred C57BLMicrobial Sensitivity TestsMycobacterium tuberculosisPlant ExtractsPleurisyRatsRats, WistarConceptsSwiss miceIL-1β levelsC57BL-6 miceEthanolic extractInflammation/infectionSafe new drugsM. tuberculosis growthMechanical hyperalgesiaInflammatory parametersOral treatmentIL-1βPleurisy modelMinimum inhibitory concentrationPharmacoeconomic perspectiveC57BL6 miceComplete adjuvantSubcutaneous injectionOral administrationWistar ratsMiceMycobacterium tuberculosisNew drugsHealth benefitsTuberculosis growthInhibitory concentration
2013
The Polyphosphate Kinase Gene ppk2 Is Required for Mycobacterium tuberculosis Inorganic Polyphosphate Regulation and Virulence
Chuang YM, Belchis DA, Karakousis PC. The Polyphosphate Kinase Gene ppk2 Is Required for Mycobacterium tuberculosis Inorganic Polyphosphate Regulation and Virulence. MBio 2013, 4: 10.1128/mbio.00039-13. PMID: 23695835, PMCID: PMC3663568, DOI: 10.1128/mbio.00039-13.Peer-Reviewed Original ResearchConceptsM. tuberculosis growthMIC of isoniazidFirst-line anti-TB drug isoniazidTuberculosis growthAnti-TB drug isoniazidAcute murine infectionLungs of miceJ774 macrophagesSuccessful human pathogenM. tuberculosis virulenceIL-12p70Lung CFUIL-10Immunobead assaysKey cytokineIL-9Interleukin-2Gamma interferonMurine modelLung macrophagesMurine infectionDay 7Control groupImmune systemMouse lung
2010
Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrobial Agents And Chemotherapy 2010, 55: 567-574. PMID: 21078950, PMCID: PMC3028776, DOI: 10.1128/aac.01179-10.Peer-Reviewed Original ResearchMeSH KeywordsAcetamidesAdolescentAdultAnimalsAntitubercular AgentsArea Under CurveDose-Response Relationship, DrugDrug Administration ScheduleHumansLinezolidMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisOxazolidinonesPyrazinamideRatsSerum Bactericidal TestTreatment OutcomeTuberculosisYoung AdultConceptsPNU-100480Whole-blood bactericidal activityMultiple ascending dosesDays of dosingSerious global health threatWhole blood culturesBactericidal activityGlobal health threatM. tuberculosis growthAscending dosesSixth cohortNew tuberculosis treatmentsPlasma drugTuberculosis treatmentPlasma concentrationsSafety signalsHealthy volunteersDose selectionRoutine safety testsNew treatmentsDay 27TuberculosisMycobacterium tuberculosisDosesHealth threat
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply